Sandra Ann Springer, MD
Research & Publications
Biography
News
Locations
Research Summary
Dr. Springer's has significant clinical research experience with integrating addiction medicine and infectious disease prevention and treatment interventions. She is the Director of InSTRIDE –Integrating Substance Use Treatment Research with Infectious Disease for Everyone https://medicine.yale.edu/lab/springer/ In particular, she has focused on evaluating medication treatments for opioid and alcohol use disorders to improve HIV treatment outcomes among persons with HIV (PWH) released from prison and jail. She currently has an Independent Scientist Award (K02) from NIDA evaluating medications for opioid use disorder (OUD) (MOUD) among PWH. In addition to being a PI on her NIDA-Independent Scientist K02 award, she is currently MPI on 6 grants: (1) a 5 year R01 from NIDA evaluating the impact of medication treatment for opioid use disorder (MOUD) on immunologic outcomes among persons with opioid use disorder (OUD) living with HIV and without HIV infection with colleague Dr. Albert Shaw; (2) a PI on a NIDA funded R33/R61that is evaluating the impact of all forms of MOUD on HIV persistence with colleagues at Yale , Drs. Ya-Chi Ho and Yuval Kluger; (3) the contact PI of a multisite NCATS U01 that is evaluating the integration of infectious disease treatment and OUD treatment with injectable buprenorphine in hospitalized patients with OUD with co-PIs Dr. Edward Nunes, Frances Levin and Kathleen Brady; (4) a co-PI for a VA COOP comparative effectiveness RCT of injectable and sublingual buprenorphine among 900 Veterans with OUD across 20 VA national sites with co-PI Dr. Ismene Petrakis; (5) an MPI on a NIDA JCOIN HEALing award performing a 5 multisite RCT comparing long acting buprenorphine to XR-NTX for persons in prison and jail with OUD with MPIs Dr. Joshua Lee (contact), Lisa Marsch, Robert Schwartz, Elizabeth Waddell and David Farabee; (6) contact PI of a NIDA JCOIN HEALing award that is a hybrid type 1 implementation effectiveness RCT comparing mobile health unit and patient navigation community linkage programs to improve OUD and HIV prevention (PrEP) and treatment (ART) services for persons in prison and jail with co-PIs Drs. Kevin Knight and Ank Nijhawan; (7) and I am a co-I on a NIDA HEALing Communities U01 for persons with OUD in NY state where I co-lead the CJS sub-group (PIs: Drs. Nabila El-Bassel, Edward Nunes, Louisa Gilbert, Daniel Feaster.
Specialized Terms: HIV, HIV prevention, Pre-exposure prophylaxis, PrEP, Opioid use disorder, Medication treatment for Opioid use disorder, buprenorphine, extended-release naltrexone, criminal justice involved persons, persons who use drugs (PWUD), Veterans.
Extensive Research Description
I am fortunate to have had considerable success as an independent investigator starting with early research experiences as an undergraduate at Harvard1-3and during my training as an Infectious Disease Fellow. I have focused my entire research career on developing and evaluating interventions for persons affected by substance use disorders and related infectious diseases, in particular those living with or at risk for HIV; and I have been continuously NIH funded since my NIDA K23 award in 2005. I am considered one of the leaders in clinical research at the intersection ID/HIV and substance use disorders. My work in particular has specifically addressed two intersecting epidemics in this country: the opioid epidemic and the HIV epidemic. My research has shown that medication treatment of opioid use disorder, as well as alcohol use disorder, in persons with HIV improves HIV viral suppression as well as substance use outcomes. This is in line with the goals of the United States Ending the HIV Epidemic (EHE) plan to reduce new HIV infections by 90% by 20304. Most importantly, I have shown that in order to achieve these goals; we must integrate treatment of opioid use disorder (OUD) with medication treatment of OUD (MOUD) (e.g. buprenorphine, methadone, extended-release naltrexone (XR-NTX)) with HIV treatment and prevention services.
During my ID fellowship at Yale, my research identified that persons with HIV who are incarcerated lose viral suppression (VS) within 3 months after release5,6and surmised that relapse to substance use interfered with the HIV care cascade7,8. During my NIDA K23 award that launched my research career I developed the first protocol to use buprenorphine (BPN) as relapse prevention for persons with OUD and HIV transitioning to the community from prison and jail. This pilot study confirmed that BPN was not only well-accepted and tolerated, but it decreased relapse to opioid use and improved HIV VS 6 months after release.9,10 I also evaluated the impact of depression on HIV antiretroviral therapy (ART) adherence among released prisoners with HIV transitioning to the community.11In addition during this time I also created rapid OUD diagnostic tool for non-clinicians called the Rapid Opioid Dependency Screen (RODS)12 that is freely available and is being used by multiple clinical and justice settings to aid in diagnosing OUD. This early body of innovative work was the foundation of my career of continued innovations in integration of treatment of OUD and ID/HIV. After that early BPN pilot project I was awarded two R01s (NIAAA and NIDA) back to back that evaluated the effect of a monthly injectable medication treatment, XR-NTX, in the only ever double blind placebo controlled trials among PWH with AUD and OUD respectively, and both found that XR-NTX achieved and maintained HIV VS 6 months after release from prison and jail.13-18 Further our recent systematic review and meta-analysis of published studies of MOUD on infectious disease outcomes that we just completed also showed that MOUD improves VS19. These innovative studies established that medication treatment of the OUD (and AUD) combined with HIV treatment leads to HIV VS, the goal of treatment of HIV and public health, as it is TREATMENT AS PREVENTION20. Persons living with HIV cannot transmit HIV to uninfected persons if they have VS, thus incorporating MOUD is essential to the goals of the EHE plan.
This early work then led to ground-breaking new collaborations including those within and outside of my discipline to advance further innovative research including: with addiction psychiatrists like Drs. Ned Nunes, Frances Levin & Kathleen Brady on a current innovative research study integrating MOUD into hospital settings in those with concurrent infections related to OUD using long-acting injectable buprenorphine where I am contact PI (NCATS U01TR002763)21; with Dr. Ismene Petrakis at the Veterans Administration in CT where we are co-PIs on the first VA National 20 multisite study comparing two forms of buprenorphine (monthly injectable and daily sublingual) in 900 Veterans with OUD (VA CSP#2014); with basic science researchers evaluating how MOUD affects inflammation and HIV latency with innovative NIH awards as contact PI collaborating with Drs. Albert Shaw (NIDA R01DA043337)22and Ya-Chi Ho & Yuval Kluger (NIDA R61/R33 DA047037)); with implementation scientists (Dr. Nabila El-Bassel) through work on the NY state HEALing communities award (UM1DA049415); with implementation researcher Dr. Kevin Knight and ID specialist Ank Nijhawan on our $11.5 million NIDA U01DA053039 (new JCOIN hub) where I am contact PI, to compare mobile health unit provision of services to patient navigator services for persons who use drugs released from justice settings to link to PrEP/ART and MOUD23, that is also harmonizing with all of JCOIN hubs and HPTN 094 (Steve Shoptaw & Nabila El-Bassel, PIs); with technology researchers working at the interface of OUD like Dr. Sean Young; with public health expert Gregg Gonsalves where we are evaluating the effect of MOUD on VS in Veterans with HIV and OUD; and with addiction medicine specialists like Josh Lee where we are MPIs with Liz Waddell, Robert Schwartz, David Farabee, & Lisa Marsch on a NIDA JCOIN funded RCT (U01DA047982)24comparing injectable buprenorphine to injectable naltrexone in persons in prison and jail. I currently have 10 grants, of which I am PI of 7 of them. Through work collaborating with others in research, clinical work and on national committees, I have been able to more broadly discuss the importance of integration of HIV and addiction prevention and treatment services and translate science into action with policy briefs and changes in national guidelines also.25-30
References:
1. Springer SA, Gastfriend DR. A pilot study of factors associated with resilience to substance abuse in adolescent sons of alcoholic fathers. J Addict Dis. 1995;14(2):53-66.
2. Levin JM, Holman BL, Mendelson JH, et al. Gender differences in cerebral perfusion in cocaine abuse: technetium-99m-HMPAO SPECT study of drug-abusing women. J Nucl Med. 1994;35(12):1902-1909.
3. Teoh SK, Sarnyai Z, Mendelson JH, et al. Cocaine effects on pulsatile secretion of ACTH in men. J Pharmacol Exp Ther. 1994;270(3):1134-1138.
4. Ending the HIV Epidemic : A Plan For America. 2019. https://www.cdc.gov/endhiv/index.html
. Accessed April 10, 2020.
5. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754-1760.
6. Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials. 2007;8(4):205-212.
7. Springer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011;53(5):469-479.
8. Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. The American journal of drug and alcohol abuse. 2011;37(1):12-21.
9. Springer S, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes For Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment Journal of Urban Health. 2010.
10. Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS ONE. 2012;7(5):e38335.
11. Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009;21(8):976-983.
12. Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS). J Correct Health Care. 2015;21(1):12-26.
13. Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial. J Acquir Immune Defic Syndr. 2018;79(1):92-100.
14. Springer SA, Di Paola A, Azar MM, et al. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial. J Acquir Immune Defic Syndr. 2018;78(1):43-53.
15. Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials. 2014;39(2):256-268.
16. Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemp Clin Trials. 2014;37(2):209-218.
17. Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug Alcohol Depend. 2015;157:158-165.
18. Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend. 2017;174:158-170.
19. McNamara K, Biondi BE, Hernandez-Ramirez RU, Taweh N, Grimshaw AA, Springer SA. A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes. Open Forum Infect Dis. 2021.
20. Springer SA, Larney S, Alam-Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions. J Acquir Immune Defic Syndr. 2015;69 Suppl 1:S155-S161.
21. Seval N, Frank C, Litwin AH, et al. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. Contemp Clin Trials. 2021;Jun(105).
22. Biondi BE, Mohanty S, Wyk BV, Montgomery RR, Shaw AC, Springer SA. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemp Clin Trials Commun. 2021;Jan 6(21).
23. Taweh N, Schlossberg E, Frank C, et al. Linking Criminal Justice-Involved Individuals to HIV, Hepatitis C, and Opioid Use Disorder Prevention and Treatment Services Upon Release to the Community: Progress, Gaps, and Future Directions. International Journal of Drug Policy. 2021.
24. Waddell EN, Springer SA, Marsch L, et al. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). J Subst Abuse Treat. 2021;Apr 8.
25. Springer SA, Korthuis PT, Del Rio C. Integrating Treatment at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics in Medical Settings: A Call for Action After a National Academies of Sciences, Engineering, and Medicine Workshop. Ann Intern Med. 2018;169(5):335-336.
26. Springer SA, Merluzzi AP, Del Rio C. Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics: A Report From the National Academies of Sciences, Engineering, and Medicine. JAMA.2020.
27. Seval N, Eaton E, Springer SA. Beyond Antibiotics: A Practical Guide for the Infectious Disease Physician to Treat Opioid Use Disorder in the Setting of Associated Infectious Diseases. Open Forum Infect Dis. 2020;7(1):ofz539.
28. Springer SA, Barocas JA, Wurcel A, et al. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda. Journal of Infectious Diseases. 2020;222(Suppl 5):S230-238.
29. Springer SA, Biondi BE, Frank C, El-Bassel N. A Call to Action to Combat the Opioid Epidemic among Women. J Addict Med. 2020.
30. Serota DP, Barocas JA, Springer SA. Infectious complications of addiction: A call for a new subspecialty within infectious diseases. Cain Infect Dis. 2019.
Coauthors
Research Interests
Acquired Immunodeficiency Syndrome; Alcoholism; Buprenorphine; HIV; Naltrexone; Opioid-Related Disorders; Prisoners; Risk-Taking; Randomized Controlled Trial; Substance-Related Disorders; Pre-Exposure Prophylaxis; Addiction Medicine
Public Health Interests
Behavioral Health; Clinical Trials; HIV/AIDS; Infectious Diseases; Substance Use, Addiction; Pharmaceuticals and Medical Devices
Selected Publications
- Co-calibration of two self-reported measures of adherence to antiretroviral therapy.Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care 2017, 29: 464-468. PMID: 27910703, PMCID: PMC5291764, DOI: 10.1080/09540121.2016.1263721.
- Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium.Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium. AIDS And Behavior 2017, 21: 2945-2957. PMID: 28188460, PMCID: PMC5552433, DOI: 10.1007/s10461-017-1722-9.
- Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.
- Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice FL. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug And Alcohol Dependence 2016, 165: 213-20. PMID: 27370527, PMCID: PMC5094181, DOI: 10.1016/j.drugalcdep.2016.06.011.
- HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study.Vagenas P, Zelenev A, Altice FL, Di Paola A, Jordan AO, Teixeira PA, Frew PM, Spaulding AC, Springer SA. HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study. AIDS Care 2016, 28: 22-31. PMID: 26275122, PMCID: PMC4713253, DOI: 10.1080/09540121.2015.1062464.
- Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS).Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS). Journal Of Correctional Health Care : The Official Journal Of The National Commission On Correctional Health Care 2015, 21: 12-26. PMID: 25559628, PMCID: PMC4435561, DOI: 10.1177/1078345814557513.
- Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions.Springer SA, Larney S, Alam-Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions. Journal Of Acquired Immune Deficiency Syndromes (1999) 2015, 69 Suppl 2: S155-61. PMID: 25978482, PMCID: PMC4443704, DOI: 10.1097/QAI.0000000000000637.
- Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.Springer SA, Brown SE, Di Paola A, Altice FL. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157: 158-65. PMID: 26560326, PMCID: PMC4675147, DOI: 10.1016/j.drugalcdep.2015.10.023.
- Correction: The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model.Lima VD, Graf I, Beckwith CG, Springer S, Altice FL, Coombs D, Kim B, Messina L, Montaner JS, Spaulding A. Correction: The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. PloS One 2015, 10: e0128734. PMID: 25978721, PMCID: PMC4433341, DOI: 10.1371/journal.pone.0128734.
- Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 2014, 39: 256-68. PMID: 25240704, PMCID: PMC4283549, DOI: 10.1016/j.cct.2014.09.002.
- HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study.Meyer JP, Cepeda J, Springer SA, Wu J, Trestman RL, Altice FL. HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. The Lancet. HIV 2014, 1: e77-e84. PMID: 25473651, PMCID: PMC4249702, DOI: 10.1016/S2352-3018(14)70022-0.
- A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community.Di Paola A, Altice FL, Powell ML, Trestman RL, Springer SA. A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community. Health & Justice 2014, 2 PMID: 25606368, PMCID: PMC4297667, DOI: 10.1186/s40352-014-0011-1.
- Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials 2014, 37: 209-18. PMID: 24384538, PMCID: PMC3992862, DOI: 10.1016/j.cct.2013.12.006.
- An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Abuse Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.
- Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Internal Medicine 2014, 174: 721-9. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.
- Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail.Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS And Behavior 2013, 17 Suppl 2: S118-27. PMID: 23673792, PMCID: PMC3818019, DOI: 10.1007/s10461-013-0506-0.
- Adherence to HIV treatment and care among previously homeless jail detainees.Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, Spaulding AC, Springer SA, Altice FL. Adherence to HIV treatment and care among previously homeless jail detainees. AIDS And Behavior 2013, 17: 2654-66. PMID: 22065234, PMCID: PMC3325326, DOI: 10.1007/s10461-011-0080-2.
- Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study.Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study. AIDS And Behavior 2013, 17 Suppl 2: S171-80. PMID: 23142854, PMCID: PMC3600070, DOI: 10.1007/s10461-012-0362-3.
- Partner violence and health among HIV-infected jail detainees.Meyer JP, Wickersham JA, Fu JJ, Brown SE, Sullivan TP, Springer SA, Altice FL. Partner violence and health among HIV-infected jail detainees. International Journal Of Prisoner Health 2013, 9: 124-41. PMID: 24376468, PMCID: PMC3873166, DOI: 10.1108/IJPH-03-2013-0011.
- Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes.Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials 2012, 33: 436-44. PMID: 22101218, PMCID: PMC3268833, DOI: 10.1016/j.cct.2011.11.002.
- The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review.Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS And Behavior 2012, 16: 2119-43. PMID: 22644066, PMCID: PMC3481055, DOI: 10.1007/s10461-012-0212-3.
- Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners.Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PloS One 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.
- Public health implications for adequate transitional care for HIV-infected prisoners: five essential components.Springer SA, Spaulding AC, Meyer JP, Altice FL. Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2011, 53: 469-79. PMID: 21844030, PMCID: PMC3156144, DOI: 10.1093/cid/cir446.
- Improving healthcare for incarcerated women.Springer SA. Improving healthcare for incarcerated women. Journal Of Women's Health (2002) 2010, 19: 13-5. PMID: 20088653, PMCID: PMC2828190, DOI: 10.1089/jwh.2009.1786.
- Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. Journal Of Urban Health : Bulletin Of The New York Academy Of Medicine 2010, 87: 592-602. PMID: 20177974, PMCID: PMC2900572, DOI: 10.1007/s11524-010-9438-4.
- Commentary on Larney (2010): a call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners.Springer SA. Commentary on Larney (2010): a call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners. Addiction (Abingdon, England) 2010, 105: 224-5. PMID: 20078481, PMCID: PMC2825564, DOI: 10.1111/j.1360-0443.2009.02893.x.
- Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy.Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009, 21: 976-83. PMID: 20024753, PMCID: PMC2797133, DOI: 10.1080/09540120802657555.
- A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners.Springer SA, Bruce RD. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. Journal Of Opioid Management 2008, 4: 81-6. PMID: 18557164, PMCID: PMC2476214, DOI: 10.5055/jom.2008.0012.
- Antiretroviral treatment regimen outcomes among HIV-infected prisoners.Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clinical Trials 2007, 8: 205-12. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.
- Managing HIV/AIDS in correctional settings.Springer SA, Altice FL. Managing HIV/AIDS in correctional settings. Current HIV/AIDS Reports 2005, 2: 165-70. PMID: 16343373, DOI: 10.1007/s11904-005-0011-9.
- Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection.Altice FL, Marinovich A, Khoshnood K, Blankenship KM, Springer SA, Selwyn PA. Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection. Journal Of Urban Health : Bulletin Of The New York Academy Of Medicine 2005, 82: 312-26. PMID: 15872190, PMCID: PMC3456574, DOI: 10.1093/jurban/jti055.
- Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community.Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2004, 38: 1754-60. PMID: 15227623, DOI: 10.1086/421392.
- Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort.Fredericksen RJ, Whitney BM, Trejo E, Nance RM, Fitzsimmons E, Altice FL, Carrico AW, Cleland CM, Del Rio C, Duerr A, El-Sadr WM, Kahana S, Kuo I, Mayer K, Mehta S, Ouellet LJ, Quan VM, Rich J, Seal DW, Springer S, Taxman F, Wechsberg W, Crane HM, Delaney JAC. Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort. BMC Public Health 2021, 21: 2002. PMID: 34736425, PMCID: PMC8567631, DOI: 10.1186/s12889-021-12026-7.
- Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence.Schultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, Springer SA. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. Contemporary Clinical Trials Communications 2021, 24: 100866. PMID: 34825103, PMCID: PMC8605182, DOI: 10.1016/j.conctc.2021.100866.
- Feasibility of a community-based delivery model for HIV pre-exposure prophylaxis among bar patrons in rural South Africa.Grammatico MA, Moll AP, Choi K, Springer SA, Shenoi SV. Feasibility of a community-based delivery model for HIV pre-exposure prophylaxis among bar patrons in rural South Africa. Journal Of The International AIDS Society 2021, 24: e25848. PMID: 34826363, PMCID: PMC8625837, DOI: 10.1002/jia2.25848.
- Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson R. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice 2022, 17: 6. PMID: 35101115, PMCID: PMC8802273, DOI: 10.1186/s13722-022-00286-6.
- Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addiction Science & Clinical Practice 2022, 17: 15. PMID: 35255967, PMCID: PMC8899775, DOI: 10.1186/s13722-022-00299-1.
- Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons.Springer SA, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. BMC Infectious Diseases 2022, 22: 380. PMID: 35428213, PMCID: PMC9013109, DOI: 10.1186/s12879-022-07354-x.
Clinical Trials
Conditions | Study Title |
---|---|
HIV/AIDS | Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence |
Addictive Behaviors; HIV/AIDS; Infectious Diseases | Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures |